Login to Your Account

Shares Nearly Double

Avanir Moves Double-Time to Market with Nuedexta

By Tom Wall

Tuesday, November 2, 2010
Shares of Avanir Pharmaceuticals Inc. nearly doubled as the company rapidly shifted into commercialization mode following FDA approval late Friday of Nuedexta (dextromethorphan hydrobromide and quinidine sulfate), the first and only FDA-approved treatment for pseudobulbar affect (PBA). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription